Core Viewpoint - Kamada Ltd. has received a tax ruling from the Israel Tax Authority regarding a cash dividend of $0.25 per share, totaling approximately $14.4 million, which is set to be paid on April 7, 2026, to shareholders of record as of March 23, 2026 [1] Tax Ruling and Dividend Details - The tax ruling allows eligible Nasdaq shareholders from countries with a tax treaty with Israel to benefit from a reduced withholding tax rate on the dividend [2] - Israeli corporate shareholders may qualify for an exemption from Israeli withholding tax under the ruling [2][6] Withholding Tax Procedures - The current Israeli withholding tax rate is 30% for substantial shareholders and 25% for other shareholders [5] - On the payment date, 25% of the dividend will be withheld and remitted to the tax agent, with the remaining 75% distributed to shareholders [6] - Nasdaq shareholders must submit required documentation to the tax agent by May 9, 2026, to claim the reduced withholding tax rate [6][9] Documentation Requirements - Required documentation includes bank account details, identification, proof of residency, and declarations regarding share ownership and tax residency [6][7] - Non-Israeli corporate shareholders must provide additional documentation regarding their shareholders or partners [7][13] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio of FDA-approved specialty plasma-derived products [11] - The company aims for growth through organic expansion, distribution partnerships, plasma collection operations, and potential mergers and acquisitions [11]

Core Insights - The U.S. FDA has approved Kamada Ltd.'s plasma collection center in San Antonio, Texas, allowing it to commence commercial sales of normal source plasma [1][2][3] - The San Antonio facility is designed to support up to 50 donor beds and has a planned capacity of approximately 50,000 liters of plasma per year, making it one of the largest specialty plasma collection centers in the U.S. [2][6] - The center is expected to generate annual revenues between $8 million to $10 million at full capacity [3][6] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio that includes six FDA-approved specialty plasma-derived products [4] - The company is controlled by FIMI Opportunity Funds, which owns approximately 38% of its outstanding shares [4] - Kamada's growth strategy includes organic growth of its commercial portfolio, distribution of third-party pharmaceutical products, ramping up plasma collection operations, and pursuing mergers and acquisitions [4] Operational Capacity - The San Antonio center adds to Kamada's existing three FDA-approved plasma collection centers located in Beaumont, Houston, and San Antonio, enhancing its capacity for specialty and normal source plasma collection [3][4] - The facility is structured to collect both normal source plasma and specialty plasma, including anti-rabies and anti-D plasma [6]

Core Viewpoint - Kamada Ltd. reported strong financial performance for 2025, achieving record revenues and adjusted EBITDA, and is optimistic about continued growth in 2026 with affirmed guidance [2][5][10]. Financial Performance - Total revenues for 2025 were $180.5 million, a 12% increase from $161.0 million in 2024 [6]. - Adjusted EBITDA for 2025 was $42.0 million, reflecting a 23% increase from $34.1 million in 2024 [5][13]. - Net income for 2025 was $20.2 million, a 40% increase compared to $14.5 million in 2024 [5][6]. - The company generated $25.5 million in cash from operating activities in 2025, contributing to a cash position of $75.5 million at year-end [2][5]. 2026 Guidance - Kamada affirmed its 2026 annual guidance, projecting revenues between $200 million and $205 million, and adjusted EBITDA between $50 million and $53 million, representing year-over-year growth of 13% and 23% respectively [2][10][19]. Strategic Focus - The company plans to expand its commercial product portfolio, invest in the commercialization of FDA-approved specialty plasma-derived products, and grow its Distribution segment through new biosimilar products [3][19]. - Kamada aims to enhance plasma collection operations to support revenue growth and reduce costs [3][19]. - The company is also looking to secure new business development and M&A transactions to accelerate profitable growth and enrich its product portfolio [5][19]. Dividend Policy - Kamada adopted an annual cash dividend policy, declaring a cash dividend of $0.25 per share, totaling approximately $14.4 million, to be paid on April 6, 2026 [5][14]. Recent Developments - The company announced a $10 million to $14 million extension of an existing tender with Canadian Blood Services for the supply of specialty plasma-derived products [14]. - Kamada discontinued its Phase 3 Inhaled AAT clinical trial [14].

Core Viewpoint - Kamada Ltd. reported record revenue and profitability for the full year 2025 and declared a cash dividend of $0.25 per share, totaling approximately $14.4 million, to be paid on April 6, 2026 [1][2][3] Financial Performance - The company announced strong financial results for 2025, which supported the decision to distribute a cash dividend [3] - The cash dividend represents at least 50% of the company's annual net income, as per the newly adopted annual cash dividend policy [2] Dividend Policy - The Board of Directors has adopted a policy to distribute an annual dividend of at least 50% of net income, subject to discretion and legal requirements [2] - The dividend payment will be subject to tax withholding in accordance with Israeli tax law [3] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio of specialty plasma-derived products [4] - The company is controlled by FIMI Opportunity Funds, which owns approximately 38% of the outstanding shares [4] Growth Strategy - Kamada's growth strategy includes organic growth of its commercial portfolio, distribution of third-party pharmaceutical products, ramping up plasma collection operations, and pursuing mergers and acquisitions [4] - The company aims to enhance its marketed products portfolio and leverage its financial strength for long-term growth [4]

Core Viewpoint - Kamada Ltd. is set to release its financial results for Q4 and the fiscal year ending December 31, 2025, on March 11, 2026, before U.S. market opening [1] Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in products for rare and serious conditions, particularly in the specialty plasma-derived therapies field [3] - The company is controlled by FIMI Opportunity Funds, which owns approximately 38% of its outstanding shares [3] Growth Strategy - Kamada's growth strategy focuses on four primary pillars: 1. Organic growth of its specialty plasma therapies portfolio, including six FDA-approved products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF®, and HEPAGAM B®, along with KAMRAB® and equine-based anti-snake venom products [3] 2. Distribution of third-party pharmaceutical products in Israel and MENA through in-licensing partnerships, including the launch of several biosimilar products [3] 3. Expansion of plasma collection operations to support revenue growth from the sale of normal source plasma and meet the demand for hyper-immune plasma, with three operating centers in Texas [3] 4. Pursuit of mergers, acquisitions, and collaborations to enhance its product portfolio and leverage financial strength for long-term growth [3]

Core Viewpoint - Kamada Ltd. has secured a two-year extension of a tender from Canadian Blood Services for the supply of four specialty plasma-derived products, valued between $10 million to $14 million, ensuring ongoing sales in the Canadian market from Q2-26 to Q1-28 [1][4]. Group 1: Company Performance and Financial Guidance - The tender extension is expected to secure ongoing sales of approximately $5 million to $7 million per year during the contract period [5]. - Kamada has reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million [2][5]. - The company projects double-digit growth in revenues and profitability for 2026, supported by its robust commercial portfolio and expansion of normal source plasma sales [2][5]. Group 2: Strategic Positioning and Future Outlook - The CEO of Kamada emphasized the company's leading position in the specialty plasma-derived products market in Canada and expressed confidence in the commercial potential of its AAT and specialty immunoglobulin portfolio in international markets [2][5]. - The company aims to pursue additional contracts in key strategic territories to enhance its market presence [2][5]. - Kamada's growth strategy includes organic growth from commercial activities, securing new business development opportunities, and expanding plasma collection operations to support revenue growth [3].

Core Insights - Kamada Ltd. announced the discontinuation of the Phase 3 InnovAATe trial for Inhaled AAT due to an interim futility analysis indicating low likelihood of achieving statistically significant benefits in lung function [1][5] - The company remains committed to supporting the Alpha-1 Antitrypsin Deficiency (AATD) community through its existing product GLASSIA and is focused on future growth prospects despite the trial's outcome [2][5] Financial Guidance - Kamada reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million [2][5] - The company projects double-digit growth in revenues and profitability for 2026, with detailed guidance to be provided in January 2026 [2][5] Business Strategy - Kamada's growth strategy includes organic growth from its commercial activities, business development opportunities, and expansion of plasma collection operations [4][6] - The company currently operates three plasma collection centers in the U.S. and aims to enhance its marketed products portfolio through potential collaborations and acquisitions [4][6] Company Overview - Kamada is a global biopharmaceutical company specializing in products for rare and serious conditions, particularly in the specialty plasma-derived therapies field [4][6] - The company is controlled by FIMI Opportunity Funds, which owns approximately 38% of its outstanding shares [6]

Core Insights - Kamada Ltd. will release its financial results for Q3 and the nine months ending September 30, 2025, on November 10, 2025, before U.S. market opening [1] - An investment community conference call will be held on the same day at 8:30 AM ET to discuss the results and answer questions [2] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, specializing in plasma-derived therapies [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products and is expanding its product offerings through biosimilars and new business development opportunities [3] - Kamada operates three plasma collection centers in Texas, supporting revenue growth through the sale of normal source plasma and hyper-immune plasma [3] - The company is advancing its lead product candidate, Inhaled AAT, through the InnovAATe clinical trial, a pivotal Phase 3 trial [3] - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3]

Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in products for rare and serious conditions, particularly in the specialty plasma-derived therapies field [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B®, along with other proprietary products [3] Growth Strategy - Kamada's growth strategy is built on four primary pillars: 1. Organic growth through commercialization and life cycle management of proprietary products [3] 2. Securing new business development opportunities, including in-licensing, collaborations, and mergers and acquisitions to enhance its product portfolio [3] 3. Expanding plasma collection operations to support revenue growth and meet increasing demand for hyper-immune plasma [3] 4. Advancing the development and commercialization of additional product candidates, with a focus on unmet medical needs, such as the Inhaled AAT product candidate currently in a pivotal Phase 3 trial [3] Leadership and Events - Amir London, the CEO of Kamada, will present at the Stifel 2025 Healthcare Conference on November 12, 2025, and will be available for one-on-one investor meetings [2]

Core Insights - Kamada Ltd. has received FDA approval for its plasma collection center in Houston, Texas, allowing it to commence commercial sales of normal source plasma [1][2][3] - The Houston facility is expected to have an annual collection capacity of approximately 50,000 liters of plasma and generate estimated annual revenues of $8 million to $10 million at full capacity [2][6] - The company plans to seek approval from the European Medicines Agency (EMA) for the Houston center following the FDA approval [3][7] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio that includes six FDA-approved specialty plasma-derived products [4] - The company's growth strategy includes organic growth from commercial activities, new business development, expansion of plasma collection operations, and advancing product candidates through R&D [4] - Kamada currently operates three plasma collection centers in Texas: Houston, San Antonio, and Beaumont, which collectively enhance its capacity for specialty and normal source plasma collection [3][4]